Sverige - svenska - Läkemedelsverket (Medical Products Agency)

eql pharma ab - doxycyklinmonohydrat - tablett - 100 mg - laktosmonohydrat hjälpämne; doxycyklinmonohydrat 105,8 mg aktiv substans - doxycyklin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

galderma nordic ab - doxycyklinmonohydrat - kapsel med modifierad frisättning, hård - 40 mg - doxycyklinmonohydrat 31,2 mg aktiv substans; doxycyklinmonohydrat 10,42 mg aktiv substans; allurarött ac aluminiumlack hjälpämne; propylenglykol hjälpämne; sockersfärer hjälpämne - doxycyklin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

elanco gmbh - tiamulinvätefumarat - premix till medicinfoder - 20 mg/g - tiamulinvätefumarat 20 g aktiv substans - tiamulin - svin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

salus haus gmbh & co kg - pimpinella anisum (anis) frukt / carum carvi (kummin) frukt / foeniculum vulgare (bitterfänkål) frukt / polygonum aviculare (trampört) ört / tilia cordata (lind) blomma / thymus vulgaris (timjan) ört; vattendestillat; bergtallolja; bitterfänkålsolja; citronolja; eukalyptusolja; pepparmyntolja; stjärnanisolja - sirap - pimpinella anisum (anis) frukt / carum carvi (kummin) frukt / foeniculum vulgare (bitterfänkål) frukt / polygonum aviculare (trampört) ört / tilia cordata (lind) blomma / thymus vulgaris (timjan) ört; vattendestillat 192,53 mg aktiv substans; sackaros hjälpämne; etanol, vattenfri hjälpämne; bitterfänkålsolja 0,15 mg aktiv substans; stjärnanisolja 0,15 mg aktiv substans; eukalyptusolja 0,09 mg aktiv substans; pepparmyntolja 0,09 mg aktiv substans; bergtallolja 0,71 mg aktiv substans; citronolja 0,26 mg aktiv substans - medel mot hosta och förkylning

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

roche ab - ceftriaxonnatrium (hemiheptahydrat); lidokainhydrokloridmonohydrat - pulver och vätska till injektionsvätska, lösning - 1 g - ceftriaxonnatrium (hemiheptahydrat) 1,19 g aktiv substans; lidokainhydrokloridmonohydrat 37,34 mg aktiv substans - kombinationer

Europeiska unionen - svenska - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - prekursorcell lymfoblastisk leukemi-lymfom - antineoplastiska medel - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Europeiska unionen - svenska - EMA (European Medicines Agency)

navidea biopharmaceuticals europe ltd. - tilmanocept - radionuklid imaging - tumörens upptäckt, diagnostiska radiofarmaka - detta läkemedel är endast för diagnostisk användning. radioaktivt märkt lymphoseek är indicerat för bildbehandling och intraoperativ upptäckt av sentinel lymfkörtlar tömning av en primär tumör hos vuxna patienter med bröstcancer, melanom, eller lokal skivepitelcancer i munhålan. externa bild-och intraoperativ bedömning kan utföras med hjälp av en gamma upptäckt enhet.

Europeiska unionen - svenska - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab - melanoma; hodgkin disease; carcinoma, renal cell; carcinoma, non-small-cell lung; carcinoma, transitional cell; squamous cell carcinoma of head and neck; urologic neoplasms; mesothelioma; colorectal neoplasms - antineoplastiska medel - melanomaopdivo as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older. relative to nivolumab monotherapy, an increase in progression free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression. adjuvant treatment of melanomaopdivo as monotherapy is indicated for the adjuvant treatment of adults and adolescents 12 years of age and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. non-small cell lung cancer (nsclc)opdivo in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. opdivo as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer after prior chemotherapy in adults. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. malignant pleural mesothelioma (mpm)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. renal cell carcinoma (rcc)opdivo as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults. opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with intermediate/poor risk advanced renal cell carcinoma. opdivo in combination with cabozantinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma. classical hodgkin lymphoma (chl)opdivo as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant (asct) and treatment with brentuximab vedotin. squamous cell cancer of the head and neck (scchn)opdivo as monotherapy is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum based therapy. urothelial carcinomaopdivo as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum containing therapy. adjuvant treatment of urothelial carcinomaopdivo as monotherapy is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (miuc) with tumour cell pd-l1 expression ≥ 1%, who are at high risk of recurrence after undergoing radical resection of miuc. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)opdivo in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy. oesophageal squamous cell carcinoma (oscc)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo as monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy. adjuvant treatment of oesophageal or gastro-oesophageal junction cancer (oc or gejc)opdivo as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy. gastric, gastro‑oesophageal junction (gej) or oesophageal adenocarcinomaopdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first‑line treatment of adult patients with her2‑negative advanced or metastatic gastric, gastro‑oesophageal junction or oesophageal adenocarcinoma whose tumours express pd-l1 with a combined positive score (cps) ≥ 5.

Europeiska unionen - svenska - EMA (European Medicines Agency)

janssen-cilag international nv - ustekinumab - psoriasis; arthritis, psoriatic; crohn disease; colitis, ulcerative - immunsuppressiva - crohns diseasestelara är indicerat för behandling av vuxna patienter med måttlig till svår aktiv crohns sjukdom som har haft ett otillräckligt svar med, förlorade svar på, eller var intoleranta mot antingen konventionell terapi eller en tnfa-antagonist eller har medicinska kontraindikationer för sådana behandlingar. ulcerös colitisstelara är indicerat för behandling av vuxna patienter med måttlig till svår aktiv ulcerös kolit som har haft ett otillräckligt svar med, förlorade svar på, eller var intoleranta mot antingen konventionell terapi eller en biologisk eller har medicinska kontraindikationer för sådana behandlingar. plack psoriasisstelara är indicerat för behandling av måttlig till svår plackpsoriasis hos vuxna som inte svarat på eller som har en kontraindikation mot, eller som är intoleranta mot andra systemiska behandlingar inklusive ciklosporin, metotrexat och psoralen ultraviolett a. pediatriska plack psoriasisstelara är indicerat för behandling av måttlig till svår plackpsoriasis hos barn och ungdomar i åldrarna 6 år och äldre, som är bristfälligt eller kontrolleras av, eller som är intoleranta mot andra systemiska behandlingar eller phototherapies. psoriasisartrit arthritisstelara, ensamt eller i kombination med metotrexat är indicerat för behandling av aktiv psoriasisartrit hos vuxna patienter, när svaret på tidigare icke-biologiska sjukdomsmodifierande antireumatiska läkemedel (dmard) terapi har varit otillräcklig.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

2care4 aps - doxycyklinmonohydrat - tablett - 100 mg - doxycyklinmonohydrat 104,1 mg aktiv substans